GSK’s Responds To FDA On Cervarix, Will Augment BLA With More Efficacy Data
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm will send final study data on the cervical cancer vaccine to FDA in the first half of 2009, and approval could come six months later.